25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ZYDUSLIFE (Zydus Lifesciences Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Zydus Lifesciences Ltd together

I guess you are interested in Zydus Lifesciences Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • ๐Ÿ“Š Fundamental Analysis (FA) โ€“ Zydus Lifesciences Ltdโ€™s Financial Insights
  • ๐Ÿ“ˆ Technical Analysis (TA) โ€“ Zydus Lifesciences Ltdโ€™s Price Targets

I'm going to help you getting a better view of Zydus Lifesciences Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Zydus Lifesciences Ltd

I send you an email if I find something interesting about Zydus Lifesciences Ltd.

1. Quick Overview

1.1. Quick analysis of Zydus Lifesciences Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Zydus Lifesciences Ltd? (30 sec.)

How much money do you get?

How much money do you get?
INR0.14
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR261.95
Expected worth in 1 year
INR431.17
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR181.24
Return On Investment
18.1%

For what price can you sell your share?

Current Price per Share
INR1,002.15
Expected price per share
INR939.09 - INR1,059
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Zydus Lifesciences Ltd (5 min.)




Live pricePrice per Share (EOD)
INR1,002.15
Intrinsic Value Per Share
INR436.13 - INR874.97
Total Value Per Share
INR698.09 - INR1,136.92

2.2. Growth of Zydus Lifesciences Ltd (5 min.)




Is Zydus Lifesciences Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$3b$2.5b$485.2m16.1%

How much money is Zydus Lifesciences Ltd making?

Current yearPrevious yearGrowGrow %
Making money$515.9m$439.9m$75.9m14.7%
Net Profit Margin20.0%20.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Zydus Lifesciences Ltd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Zydus Lifesciences Ltd?

Welcome investor! Zydus Lifesciences Ltd's management wants to use your money to grow the business. In return you get a share of Zydus Lifesciences Ltd.

First you should know what it really means to hold a share of Zydus Lifesciences Ltd. And how you can make/lose money.

Speculation

The Price per Share of Zydus Lifesciences Ltd is INR1,002. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zydus Lifesciences Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zydus Lifesciences Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR261.95. Based on the TTM, the Book Value Change Per Share is INR42.30 per quarter. Based on the YOY, the Book Value Change Per Share is INR25.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR3.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zydus Lifesciences Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.510.1%0.510.1%0.440.0%0.390.0%0.380.0%0.340.0%
Usd Book Value Change Per Share0.480.0%0.480.0%0.290.0%0.290.0%0.340.0%0.500.0%
Usd Dividend Per Share0.030.0%0.030.0%0.070.0%0.040.0%0.040.0%0.040.0%
Usd Total Gains Per Share0.520.1%0.520.1%0.360.0%0.330.0%0.370.0%0.540.1%
Usd Price Per Share10.10-10.10-11.46-9.05-7.23-6.53-
Price to Earnings Ratio19.69-19.69-26.21-23.76-20.08-20.60-
Price-to-Total Gains Ratio19.55-19.55-32.11-32.07-23.63-20.06-
Price to Book Ratio3.38-3.38-4.58-3.49-3.08-2.95-
Price-to-Total Gains Ratio19.55-19.55-32.11-32.07-23.63-20.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.42451
Number of shares87
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.04
Usd Book Value Change Per Share0.480.34
Usd Total Gains Per Share0.520.37
Gains per Quarter (87 shares)44.9432.34
Gains per Year (87 shares)179.76129.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11216817012117119
22433635025234248
33650353037351377
44867171049468506
56083989061585635
6721007107074702764
7831175125086820893
89513431430989371022
91071510161011010541151
101191678179012311711280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Zydus Lifesciences Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--42.30442.3040%25.138+68%25.277+67%29.513+43%43.659-3%
Book Value Per Share--261.951261.9510%219.647+19%225.369+16%201.612+30%187.075+40%
Current Ratio--1.8851.8850%2.153-12%1.950-3%1.704+11%1.596+18%
Debt To Asset Ratio--0.2910.2910%0.245+19%0.257+13%0.2920%0.328-11%
Debt To Equity Ratio--0.4530.4530%0.362+25%0.387+17%0.473-4%0.586-23%
Dividend Per Share--3.0063.0060%6.172-51%3.939-24%3.093-3%3.744-20%
Enterprise Value--782788444943.000782788444943.0000%939724718447.500-17%719776832569.667+9%558131893507.800+40%490723185999.833+60%
Eps--44.97544.9750%38.356+17%34.232+31%33.474+34%29.811+51%
Ev To Sales Ratio--3.4683.4680%4.940-30%3.665-5%3.051+14%2.728+27%
Free Cash Flow Per Share--50.32750.3270%22.755+121%29.821+69%24.418+106%22.956+119%
Free Cash Flow To Equity Per Share--50.32750.3270%22.755+121%29.821+69%17.745+184%15.613+222%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--874.967----------
Intrinsic Value_10Y_min--436.134----------
Intrinsic Value_1Y_max--42.389----------
Intrinsic Value_1Y_min--29.581----------
Intrinsic Value_3Y_max--161.878----------
Intrinsic Value_3Y_min--101.637----------
Intrinsic Value_5Y_max--322.979----------
Intrinsic Value_5Y_min--187.124----------
Market Cap1008397393078.500+12%891221444943.000891221444943.0000%1011516718447.500-12%800078832569.667+11%641706493507.800+39%580329019333.167+54%
Net Profit Margin--0.2000.2000%0.203-1%0.173+16%0.193+4%0.175+14%
Operating Margin----0%-0%-0%0.072-100%0.086-100%
Operating Ratio--1.0301.0300%1.103-7%1.118-8%1.154-11%1.166-12%
Pb Ratio3.826+12%3.3813.3810%4.577-26%3.495-3%3.076+10%2.953+15%
Pe Ratio22.283+12%19.69319.6930%26.208-25%23.760-17%20.078-2%20.605-4%
Price Per Share1002.150+12%885.700885.7000%1005.250-12%794.150+12%634.400+40%573.183+55%
Price To Free Cash Flow Ratio19.913+12%17.59917.5990%44.177-60%30.594-42%29.977-41%27.827-37%
Price To Total Gains Ratio22.117+12%19.54719.5470%32.107-39%32.073-39%23.634-17%20.062-3%
Quick Ratio--1.2741.2740%1.158+10%1.120+14%0.921+38%0.852+50%
Return On Assets--0.1220.1220%0.132-8%0.110+11%0.116+5%0.105+16%
Return On Equity--0.1890.1890%0.195-3%0.165+14%0.185+2%0.173+9%
Total Gains Per Share--45.31145.3110%31.309+45%29.216+55%32.606+39%47.403-4%
Usd Book Value--3004857600.0003004857600.0000%2519582400.000+19%2589635400.000+16%2328602760.000+29%2162999900.000+39%
Usd Book Value Change Per Share--0.4820.4820%0.287+68%0.288+67%0.336+43%0.498-3%
Usd Book Value Per Share--2.9862.9860%2.504+19%2.569+16%2.298+30%2.133+40%
Usd Dividend Per Share--0.0340.0340%0.070-51%0.045-24%0.035-3%0.043-20%
Usd Enterprise Value--8923788272.3508923788272.3500%10712861790.302-17%8205455891.294+9%6362703585.989+40%5594244320.398+60%
Usd Eps--0.5130.5130%0.437+17%0.390+31%0.382+34%0.340+51%
Usd Free Cash Flow--577307400.000577307400.0000%261025800.000+121%342444600.000+69%281630160.000+105%265116500.000+118%
Usd Free Cash Flow Per Share--0.5740.5740%0.259+121%0.340+69%0.278+106%0.262+119%
Usd Free Cash Flow To Equity Per Share--0.5740.5740%0.259+121%0.340+69%0.202+184%0.178+222%
Usd Market Cap11495730281.095+12%10159924472.35010159924472.3500%11531290590.302-12%9120898691.294+11%7315454025.989+39%6615750820.398+54%
Usd Price Per Share11.425+12%10.09710.0970%11.460-12%9.053+12%7.232+40%6.534+55%
Usd Profit--515907000.000515907000.0000%439983000.000+17%393121400.000+31%386829360.000+33%344713200.000+50%
Usd Revenue--2573413200.0002573413200.0000%2168451000.000+19%2221977800.000+16%2009186160.000+28%1936751700.000+33%
Usd Total Gains Per Share--0.5170.5170%0.357+45%0.333+55%0.372+39%0.540-4%
 EOD+4 -4MRQTTM+0 -0YOY+22 -153Y+29 -85Y+32 -610Y+28 -10

3.3 Fundamental Score

Let's check the fundamental score of Zydus Lifesciences Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1522.283
Price to Book Ratio (EOD)Between0-13.826
Net Profit Margin (MRQ)Greater than00.200
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.274
Current Ratio (MRQ)Greater than11.885
Debt to Asset Ratio (MRQ)Less than10.291
Debt to Equity Ratio (MRQ)Less than10.453
Return on Equity (MRQ)Greater than0.150.189
Return on Assets (MRQ)Greater than0.050.122
Total7/10 (70.0%)

3.4 Technical Score

Let's check the technical score of Zydus Lifesciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.134
Ma 20Greater thanMa 50997.328
Ma 50Greater thanMa 1001,000.109
Ma 100Greater thanMa 200979.928
OpenGreater thanClose985.650
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Zydus Lifesciences Ltd

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Fundamental data was last updated by Penke on 2025-10-20 01:50:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitย Zydus Lifesciences Ltd earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compareย Zydus Lifesciences Ltd to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 20.0%ย means thatย ₹0.20 for each ₹1ย in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zydus Lifesciences Ltd:

  • The MRQ is 20.0%. The company is making a huge profit. +2
  • The TTM is 20.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ20.0%TTM20.0%0.0%
TTM20.0%YOY20.3%-0.2%
TTM20.0%5Y19.3%+0.7%
5Y19.3%10Y17.5%+1.8%
4.3.1.2. Return on Assets

Shows howย efficientย Zydus Lifesciences Ltd is using its assets to generate profit.

  • Above 5% is considered healthyย but always compareย Zydus Lifesciences Ltd to theย Drug Manufacturers - Specialty & Generic industry mean.
  • 12.2% Return on Assets means thatย Zydus Lifesciences Ltd generatedย ₹0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zydus Lifesciences Ltd:

  • The MRQ is 12.2%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 12.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ12.2%TTM12.2%0.0%
TTM12.2%YOY13.2%-1.0%
TTM12.2%5Y11.6%+0.6%
5Y11.6%10Y10.5%+1.1%
4.3.1.3. Return on Equity

Shows how efficient Zydus Lifesciences Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareย Zydus Lifesciences Ltd to theย Drug Manufacturers - Specialty & Generic industry mean.
  • 18.9% Return on Equity means Zydus Lifesciences Ltd generated ₹0.19ย for eachย ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zydus Lifesciences Ltd:

  • The MRQ is 18.9%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 18.9%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ18.9%TTM18.9%0.0%
TTM18.9%YOY19.5%-0.6%
TTM18.9%5Y18.5%+0.4%
5Y18.5%10Y17.3%+1.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Zydus Lifesciences Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measuresย how efficient Zydus Lifesciences Ltd is operatingย .

  • Measures how much profit Zydus Lifesciences Ltd makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareย Zydus Lifesciences Ltd to theย Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%ย means the company generated ₹0.00 ย for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zydus Lifesciences Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y7.2%-7.2%
5Y7.2%10Y8.6%-1.3%
4.3.2.2. Operating Ratio

Measures how efficient Zydus Lifesciences Ltd is keepingย operating costsย low.

  • Below 1 is considered healthy (always compare toย Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.03 means that the operating costs are ₹1.03 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 1.030. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.030. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.030TTM1.0300.000
TTM1.030YOY1.103-0.073
TTM1.0305Y1.154-0.124
5Y1.15410Y1.166-0.012
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Zydus Lifesciences Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Zydus Lifesciences Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toย Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.89ย means the company has ₹1.89 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 1.885. The company is able to pay all its short-term debts. +1
  • The TTM is 1.885. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.885TTM1.8850.000
TTM1.885YOY2.153-0.268
TTM1.8855Y1.704+0.181
5Y1.70410Y1.596+0.108
4.4.3.2. Quick Ratio

Measures if Zydus Lifesciences Ltd is able to pay off Short-term Debt but only usingย theย most liquid assets.

  • Above 1 is considered healthy butย always compareย Zydus Lifesciences Ltd to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.27ย means the company can pay off ₹1.27 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 1.274. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.274. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.274TTM1.2740.000
TTM1.274YOY1.158+0.116
TTM1.2745Y0.921+0.353
5Y0.92110Y0.852+0.070
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Zydus Lifesciences Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %ย of Zydus Lifesciences Ltdย assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareย Zydus Lifesciences Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.29ย means that Zydus Lifesciences Ltd assets areย financed with 29.1% credit (debt) and the remaining percentage (100% - 29.1%)ย is financed by its owners/shareholders.ย 

Let's take a look of the Debt to Asset Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 0.291. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.291. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.291TTM0.2910.000
TTM0.291YOY0.245+0.046
TTM0.2915Y0.292-0.001
5Y0.29210Y0.328-0.036
4.5.4.2. Debt to Equity Ratio

Measures ifย Zydus Lifesciences Ltd is able toย pay off its debts by usingย shareholders equity.

  • Below 2 is considered healthy butย always compareย Zydus Lifesciences Ltd to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 45.3% means that company has ₹0.45 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 0.453. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.453. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.453TTM0.4530.000
TTM0.453YOY0.362+0.091
TTM0.4535Y0.473-0.020
5Y0.47310Y0.586-0.114
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measuresย how much money you payย for each share forย every ₹1 in earnings Zydus Lifesciences Ltd generates.

  • Above 15 is considered overpriced butย always compareย Zydus Lifesciences Ltd to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 19.69 means the investor is paying ₹19.69ย for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zydus Lifesciences Ltd:

  • The EOD is 22.283. Based on the earnings, the company is fair priced.
  • The MRQ is 19.693. Based on the earnings, the company is fair priced.
  • The TTM is 19.693. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD22.283MRQ19.693+2.589
MRQ19.693TTM19.6930.000
TTM19.693YOY26.208-6.515
TTM19.6935Y20.078-0.384
5Y20.07810Y20.605-0.527
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zydus Lifesciences Ltd:

  • The EOD is 19.913. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 17.599. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 17.599. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD19.913MRQ17.599+2.314
MRQ17.599TTM17.5990.000
TTM17.599YOY44.177-26.578
TTM17.5995Y29.977-12.378
5Y29.97710Y27.827+2.150
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofย Zydus Lifesciences Ltd is to cheap or to expensiveย compared to its book value.

  • At or below 1 is considered healthyย (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 3.38 means the investor is paying ₹3.38ย for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Zydus Lifesciences Ltd:

  • The EOD is 3.826. Based on the equity, the company is fair priced.
  • The MRQ is 3.381. Based on the equity, the company is fair priced.
  • The TTM is 3.381. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.826MRQ3.381+0.445
MRQ3.381TTM3.3810.000
TTM3.381YOY4.577-1.196
TTM3.3815Y3.076+0.305
5Y3.07610Y2.953+0.124
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets372,017,000
Total Liabilities108,433,000
Total Stockholder Equity239,531,000
 As reported
Total Liabilities 108,433,000
Total Stockholder Equity+ 239,531,000
Total Assets = 372,017,000

Assets

Total Assets372,017,000
Total Current Assets170,461,000
Long-term Assets201,556,000
Total Current Assets
Cash And Cash Equivalents 8,268,000
Short-term Investments 74,941,000
Net Receivables 40,247,000
Inventory 39,440,000
Other Current Assets 6,794,000
Total Current Assets  (as reported)170,461,000
Total Current Assets  (calculated)169,690,000
+/- 771,000
Long-term Assets
Property Plant Equipment 73,599,000
Goodwill 52,421,000
Intangible Assets 32,236,000
Long-term Assets Other 2,642,000
Long-term Assets  (as reported)201,556,000
Long-term Assets  (calculated)160,898,000
+/- 40,658,000

Liabilities & Shareholders' Equity

Total Current Liabilities90,416,000
Long-term Liabilities18,017,000
Total Stockholder Equity239,531,000
Total Current Liabilities
Short Long Term Debt 31,695,000
Accounts payable 23,058,000
Other Current Liabilities 2,663,000
Total Current Liabilities  (as reported)90,416,000
Total Current Liabilities  (calculated)57,416,000
+/- 33,000,000
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt437,000
Long-term Liabilities Other 9,000
Long-term Liabilities  (as reported)18,017,000
Long-term Liabilities  (calculated)446,000
+/- 17,571,000
Total Stockholder Equity
Retained Earnings 245,616,000
Total Stockholder Equity (as reported)239,531,000
Total Stockholder Equity (calculated)245,616,000
+/- 6,085,000
Other
Capital Stock1,006,000
Common Stock Shares Outstanding 1,006,234
Net Debt 23,427,000
Net Invested Capital 271,226,000
Net Working Capital 80,045,000
Property Plant and Equipment Gross 73,599,000



6.2. Balance Sheets Structured

Currency in INR. All numbers in thousands.

 Trend2025-03-312024-03-312023-03-312022-03-312021-03-312020-03-31
> Total Assets 
236,866,000
238,847,000
277,954,000
257,564,000
292,808,000
372,017,000
372,017,000292,808,000257,564,000277,954,000238,847,000236,866,000
   > Total Current Assets 
87,154,000
87,160,000
122,614,000
100,164,000
115,014,000
170,461,000
170,461,000115,014,000100,164,000122,614,00087,160,00087,154,000
       Cash And Cash Equivalents 
8,453,000
6,652,000
6,578,000
4,878,000
4,130,000
8,268,000
8,268,0004,130,0004,878,0006,578,0006,652,0008,453,000
       Short-term Investments 
4,943,000
4,620,000
28,470,000
7,188,000
9,667,000
74,941,000
74,941,0009,667,0007,188,00028,470,0004,620,0004,943,000
       Net Receivables 
36,632,000
31,273,000
33,403,000
44,168,000
52,202,000
40,247,000
40,247,00052,202,00044,168,00033,403,00031,273,00036,632,000
       Inventory 
27,890,000
32,362,000
37,194,000
34,133,000
34,419,000
39,440,000
39,440,00034,419,00034,133,00037,194,00032,362,00027,890,000
       Other Current Assets 
7,054,000
8,913,000
9,937,000
186,000
175,000
6,794,000
6,794,000175,000186,0009,937,0008,913,0007,054,000
   > Long-term Assets 
149,712,000
151,687,000
155,340,000
157,400,000
177,794,000
201,556,000
201,556,000177,794,000157,400,000155,340,000151,687,000149,712,000
       Property Plant Equipment 
61,937,000
63,332,000
64,226,000
69,731,000
70,492,000
73,599,000
73,599,00070,492,00069,731,00064,226,00063,332,00061,937,000
       Goodwill 
53,915,000
53,465,000
53,646,000
48,044,000
52,660,000
52,421,000
52,421,00052,660,00048,044,00053,646,00053,465,00053,915,000
       Intangible Assets 
13,868,000
12,363,000
11,272,000
10,905,000
26,110,000
32,236,000
32,236,00026,110,00010,905,00011,272,00012,363,00013,868,000
       Other Assets 
14,470,000
16,215,000
16,848,000
0
0
0
00016,848,00016,215,00014,470,000
> Total Liabilities 
119,762,000
89,551,000
87,416,000
60,681,000
71,792,000
108,433,000
108,433,00071,792,00060,681,00087,416,00089,551,000119,762,000
   > Total Current Liabilities 
82,694,000
78,613,000
78,394,000
55,307,000
53,419,000
90,416,000
90,416,00053,419,00055,307,00078,394,00078,613,00082,694,000
       Short Long Term Debt 
47,718,000
39,740,000
38,339,000
11,632,000
7,686,000
31,695,000
31,695,0007,686,00011,632,00038,339,00039,740,00047,718,000
       Accounts payable 
20,310,000
22,059,000
21,378,000
21,250,000
21,267,000
23,058,000
23,058,00021,267,00021,250,00021,378,00022,059,00020,310,000
       Other Current Liabilities 
3,941,000
5,525,000
5,470,000
510,000
396,000
2,663,000
2,663,000396,000510,0005,470,0005,525,0003,941,000
   > Long-term Liabilities 
37,068,000
10,938,000
9,022,000
5,374,000
18,373,000
18,017,000
18,017,00018,373,0005,374,0009,022,00010,938,00037,068,000
       Long term Debt 
32,146,000
6,095,000
3,621,000
0
0
0
0003,621,0006,095,00032,146,000
       Capital Lease Obligations Min Short Term Debt
274,000
241,000
249,000
317,000
356,000
437,000
437,000356,000317,000249,000241,000274,000
       Other Liabilities 
4,777,000
4,692,000
5,240,000
0
0
0
0005,240,0004,692,0004,777,000
       Long-term Liabilities Other 
17,000
10,000
3,000
0
18,000
9,000
9,00018,00003,00010,00017,000
> Total Stockholder Equity
103,757,000
129,923,000
169,996,000
175,158,000
198,295,000
239,531,000
239,531,000198,295,000175,158,000169,996,000129,923,000103,757,000
   Common Stock
1,024,000
1,024,000
1,024,000
0
0
0
0001,024,0001,024,0001,024,000
   Retained Earnings 
104,048,000
131,739,000
172,855,000
171,898,000
203,690,000
245,616,000
245,616,000203,690,000171,898,000172,855,000131,739,000104,048,000
   Capital Surplus 000000
   Treasury Stock000000
   Other Stockholders Equity 000-3,883,000-2,840,000-1,315,000



6.3. Balance Sheets

Currency in INR. All numbers in thousands.




6.4. Cash Flows

Currency in INR. All numbers in thousands.




6.5. Income Statements

Currency in INR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2025-03-31. Currency in INR. All numbers in thousands.

Gross Profit (+$)
totalRevenue225,738,000
Cost of Revenue-66,664,000
Gross Profit159,074,000159,074,000
 
Operating Income (+$)
Gross Profit159,074,000
Operating Expense-165,945,000
Operating Income59,793,000-6,871,000
 
Operating Expense (+$)
Research Development1,894,000
Selling General Administrative30,207,000
Selling And Marketing Expenses0
Operating Expense165,945,00032,101,000
 
Net Interest Income (+$)
Interest Income1,852,000
Interest Expense-935,000
Other Finance Cost-58,000
Net Interest Income859,000
 
Pretax Income (+$)
Operating Income59,793,000
Net Interest Income859,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)60,267,00059,793,000
EBIT - interestExpense = -935,000
45,255,000
46,190,000
Interest Expense935,000
Earnings Before Interest and Taxes (EBIT)061,202,000
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax60,267,000
Tax Provision-14,119,000
Net Income From Continuing Ops46,726,00046,148,000
Net Income45,255,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-859,000
 

Technical Analysis of Zydus Lifesciences Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zydus Lifesciences Ltd. The general trend of Zydus Lifesciences Ltd is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zydus Lifesciences Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Zydus Lifesciences Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Supportย is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistanceย is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zydus Lifesciences Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1,016 < 1,059 < 1,059.

The bearish price targets are: 972.00 > 969.10 > 939.09.

Know someone who trades $ZYDUSLIFE? Share this with them.๐Ÿ‘‡

Zydus Lifesciences Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theย moving averageย of the selected period.

  • Moving averages are laggingย trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zydus Lifesciences Ltd. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zydus Lifesciences Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theย momentumย of theย selected period based on two moving averages.

  • MACD is aย lagging momentumย indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zydus Lifesciences Ltd. The current macd is -5.35247385.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zydus Lifesciences Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Zydus Lifesciences Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Zydus Lifesciences Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Zydus Lifesciences Ltd Daily Moving Average Convergence/Divergence (MACD) ChartZydus Lifesciences Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zydus Lifesciences Ltd. The current adx is 16.85.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Zydus Lifesciences Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Zydus Lifesciences Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Showsย the current trend.
  • Showsย potential entry signals.
  • Showsย ย potential exit signals.
  • Can be used to placeย trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zydus Lifesciences Ltd. The current sar is 1,019.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Zydus Lifesciences Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumย indicator, meaning the signals are instant.
  • Rangesย between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zydus Lifesciences Ltd. The current rsi is 52.13. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Zydus Lifesciences Ltd Daily Relative Strength Index (RSI) ChartZydus Lifesciences Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Comparesย a certain price to multiple prices ranging over time.

  • Leadingย momentumย indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Rangesย between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zydus Lifesciences Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zydus Lifesciences Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Zydus Lifesciences Ltd Daily Stochastic Oscillator ChartZydus Lifesciences Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,ย the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zydus Lifesciences Ltd. The current cci is -0.25441131.

Zydus Lifesciences Ltd Daily Commodity Channel Index (CCI) ChartZydus Lifesciences Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zydus Lifesciences Ltd. The current cmo is 11.80.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Zydus Lifesciences Ltd Daily Chande Momentum Oscillator (CMO) ChartZydus Lifesciences Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

ย Shows the current price relative to the highest high over the last 14 days.
ย 

  • Lagging momentum indicator
  • Ranging between 0 andย -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zydus Lifesciences Ltd. The current willr is -32.6405868.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Zydus Lifesciences Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Zydus Lifesciences Ltd Daily Williams %R ChartZydus Lifesciences Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldย 

Score

Let's take a look at the Bollinger Bands of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zydus Lifesciences Ltd. The current atr is 19.21.

Zydus Lifesciences Ltd Daily Average True Range (ATR) ChartZydus Lifesciences Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

ย Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zydus Lifesciences Ltd. The current obv is 5,637,735.

Zydus Lifesciences Ltd Daily On-Balance Volume (OBV) ChartZydus Lifesciences Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zydus Lifesciences Ltd. The current mfi is 60.94.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Zydus Lifesciences Ltd Daily Money Flow Index (MFI) ChartZydus Lifesciences Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zydus Lifesciences Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-09-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-10-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Zydus Lifesciences Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zydus Lifesciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.134
Ma 20Greater thanMa 50997.328
Ma 50Greater thanMa 1001,000.109
Ma 100Greater thanMa 200979.928
OpenGreater thanClose985.650
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Zydus Lifesciences Ltd with someone you think should read this too:
  • Are you bullish or bearish on Zydus Lifesciences Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zydus Lifesciences Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zydus Lifesciences Ltd

I send you an email if I find something interesting about Zydus Lifesciences Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Zydus Lifesciences Ltd.

Receive notifications about Zydus Lifesciences Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.